NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 40,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 40,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $735,460.60. This represents a 62.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS opened at $32.60 on Thursday. The firm has a market capitalization of $3.81 billion, a P/E ratio of -18.22 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.67 and a 1-year high of $42.21. The business’s 50-day simple moving average is $32.87 and its 200-day simple moving average is $33.17.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. boosted its holdings in NewAmsterdam Pharma by 1.4% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after acquiring an additional 241,818 shares during the period. Capital World Investors grew its position in NewAmsterdam Pharma by 1.6% in the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after acquiring an additional 161,289 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc lifted its position in shares of NewAmsterdam Pharma by 15.6% during the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after purchasing an additional 393,855 shares in the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NAMS has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price on the stock. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.